

Corporate Profile

Luminex® Corporation (NASDAQ: LMNX) develops, manufactures and markets proprietary biological testing technologies, with applications throughout the life-sciences industry. This industry depends on a broad range of tests, known as "bioassays," to discover new drugs, identify new genes or simply monitor blood cholesterol levels. The in-house experts at Luminex have developed an innovative approach to bioassays, known as xMAP® technology. This groundbreaking technology enables companies and laboratories to perform bioassays more quickly and cost-effectively than with other systems, without sacrificing accuracy.

Luminex has been marketing the current generation of xMAP technology (formerly known as LabMAP®) worldwide since 1999. Thanks to its open-architecture platform, xMAP technology can be applied across a wide range of markets. In fact, xMAP technology-based systems are already in use by leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.

Escalating research and development spending, along with the evolution of pharmacogenomics, are fueling the growth of the drug discovery, clinical diagnostics and biomedical research markets - including both genomics and proteomics research. With this expansion of market opportunities, Luminex is strategically positioned for sustained growth and success.

Stock Performance

LMNX (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$26.79
Change (%)	▲ 0.20 (0.75%)
Volume	775,059
52 Week Low	\$18.62
Market Cap	\$1,195,058,956
Rolling EPS	1.16
PE Ratio	23.0079
Shares Outstanding	44,608,397

Data as of 08/17/18 4:00 p.m. ET



Recent Headlines

08/06/18 - 5:19 p.m.
Luminex Corporation Reports Second Quarter 2018 Financial Results

07/13/18 - 2:30 p.m.
Luminex Corporation Second Quarter Earnings Release Scheduled for August 6, 2018

Primary IR Contact

Matthew Scalo
Senior Director, Investor Relations
Phone: 512.336.3587
E-mail: mscalo@luminexcorp.com

Upcoming Events

There are currently no events scheduled.

06/13/18 - 9:01 a.m.
Luminex Initiates Clinical Trials for VERIGENE® II
Gastrointestinal Assay

Corporate Governance

Nachum "Homi" Shamir	President and Chief Executive Officer
Harriss T. Currie	Chief Financial Officer, Senior Vice President, Finance and Treasurer
Todd C. Bennett	Senior Vice President, Global Sales and Customer Operations
Charles J. Collins, Ph.D.	Senior Vice President, Research and Development
Nancy M. Fairchild, SPHR	Senior Vice President, Human Resources
Randall "Randy" Myers	Senior Vice President, Global Manufacturing and Quality
Richard Rew	Senior Vice President, General Counsel and Corporate Secretary
Eric S. Shapiro	Senior Vice President, Global Marketing
Steven Back	Vice President, Global Quality Assurance
David Bourne	Vice President, Business Development and Strategic Planning
Ronald D. Dunn	Vice President, Global Regulatory and Clinical Affairs
Kendel B. Martin, CPA	Vice President, Accounting
Joern Mosner, PhD	Vice President, Research and Development
David B. Oldham	Vice President, Systems Research and Development
Reid Sadler	Vice President, Sales and Marketing Americas

SEC Filings

Filing Date	Form
08/07/18	10-Q
08/06/18	8-K
06/25/18	4
06/21/18	4

Data provided by Nasdaq. Minimum 15 minutes delayed.